Small airways in asthma: Their independent contribution to the severity of hyperresponsiveness

European Respiratory Journal

Volumn 41, Issue 3, 2013, Pages 752-754

  Telenga, Eef D ^a   Van Den Berge, Maarten ^a   Hacken, Nick H T Ten ^a   Riemersma, Roland A ^a,b   Van Der Molen, Thys ^a,b   Postma, Dirkje S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HISTAMINE; TERBUTALINE;

ADULT; AGE; AIRWAY CONSTRICTION; AIRWAY OBSTRUCTION; ASTHMA; BODY HEIGHT; BRONCHUS HYPERREACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INDIVIDUALIZATION; LETTER; MAJOR CLINICAL STUDY; MALE; NEBULIZER; PATIENT CARE; PRIORITY JOURNAL; PROVOCATION TEST; SEX DIFFERENCE; SPIROMETRY; TOTAL LUNG CAPACITY;

ADULT; ASTHMA; BRONCHI; BRONCHIAL HYPERREACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HISTAMINE; HUMANS; MALE; MIDDLE AGED; OSCILLOMETRY; SPIROMETRY;

EID: 84875272022     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00170912     Document Type: Letter

References (10)

1. Jansen DF, Schouten JP, Vonk JM, et al. Smoking and airway hyperresponsiveness especially in the presence of blood eosinophilia increase the risk to develop respiratory symptoms: A 25-year follow-up study in the general adult population. Am J Respir Crit Care Med 1999; 160: 259-264.
2. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70: 171-179.
3. Simon MR, Chinchilli VM, Phillips BR, et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol 2010; 126: 527-534.
4. Currie GP, Jackson CM, Lee DK, et al. Determinants of airway hyperresponsiveness in mild asthma. Ann Allergy Asthma Immunol 2003; 90: 560-563.
5. Riemersma RA, Postma DS, Van der Molen T. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: Effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J 2012; 21: 50-56.
6. Aronsson D, Tufvesson E, Bjermer L. Comparison of central and peripheral airway involvement before and during methacholine, mannitol and eucapnic hyperventilation challenges in mild asthmatics. Clin Respir J 2011; 5: 10-18.
7. Douma WR, Kerstjens HAM, de Gooijer A, et al. Initial improvements in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline. Chest 2002; 121: 151-157.
8. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
9. Barnes N, Price D, Colice G, et al. Asthma control with extrafineparticle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon- beclometasone: A real-world observational study. Clin Exp Allergy 2011; 41: 1521-1532.
10. Cohen J, Postma DS, Douma WR, et al. Particle size matters: Diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011; 37: 532-540.